Business | Monday May 20, 2013
Drug maker Lupin fell over 4 per cent on Monday after global investment bank Credit Suisse downgraded the stocks to "neutral" from "outperform," citing unfavourable risk-reward. Credit Suisse' 12-month price target on the stock is Rs 755, which indicates the stock may already have hit its top.
www.ndtv.com/business